Risk, returns & timeframes illustration
1 min read
November 7, 2022
by
Regan Pearson

Pfizer’s triple-demic smackdown 🥊

Pfizer is doubling down on the triple-threat of winter viruses: Covid, ‘flu and respiratory virus RSV. They’re working on a new RSV vaccine for pregnant women, and partnering with BioNTech to create a combine Influenza and Covid-19 shot using mRNA technology.
1 min read
November 7, 2022
by
Regan Pearson

Pfizer’s triple-demic smackdown 🥊

Pfizer is doubling down on the triple-threat of winter viruses: Covid, ‘flu and respiratory virus RSV. They’re working on a new RSV vaccine for pregnant women, and partnering with BioNTech to create a combine Influenza and Covid-19 shot using mRNA technology.
1 min read
November 7, 2022
by
Regan Pearson

Pfizer’s triple-demic smackdown 🥊

Pfizer is doubling down on the triple-threat of winter viruses: Covid, ‘flu and respiratory virus RSV. They’re working on a new RSV vaccine for pregnant women, and partnering with BioNTech to create a combine Influenza and Covid-19 shot using mRNA technology.
Table of contents
Getting Started Investing course
Free Getting Started Course
Take your first, or next, step to becoming a confident investor with Hatch's free online course – just 10 minutes a day, for 10 days.

Sometimes things just deserve to go viral, like the Backyard Squirrel Maze. They bring people together and are good for the soul. Others, like viruses that attack our bodies and cripple our economies, deserve to be pounded into submission like a second tier WWE (WWE) wrestler. 🥊

Pfizer (PFE) has helped the world put viruses on the ropes before. It’s almost exactly two years since Pfizer and BioNTech (BNTX - ADR) dropped the news of a vaccine 90% effective in preventing COVID-19. The vaccine not only helped to free us from our weird obsession with banana bread, but was a boon for Pfizer, helping the company to almost double revenue in one year. 📈

Now Pfizer is hoping it can double down to fight a new triple threat of invisible foes. A new wave of Covid, plus surges in ’flu and the respiratory virus RSV means the US could be heading for triple-demic winter smackdown. That’s the last thing overwhelmed hospitals (and parents) need. But last week Pfizer announced a new top-tier fighter - an RSV vaccine given to mothers during pregnancy that is up to 81% effective at preventing severe cases of the illness. 💉

And in an epic John Cena/Louis Pasteur tag-team, Pfizer is again teaming up with ally BioNTech. The pair are taking a shot at producing a combined Influenza and Covid-19 vaccine cocktail using messenger RNA (mRNA) technology. 🧬

Separately, BioNTech is using the same mRNA technology to develop personalised cancer vaccines. Just like you customise your coffee order, personalised cancer vaccines could be made to order and would prompt a patient’s immune system to attack their cancer cells. MRNA specialists Moderna (MRNA) are also teaming up with heavy-hitters Merck (MRK) on a similar vaccine specifically targeting melanoma. John Cena (and Louis Pasteur) would be proud. 👨🔬

Regan Pearson
Finance writer
Linkedin

We’re not financial advisors and Hatch news is for your information only. However dazzling our writing, none of it is a recommendation to invest in any of the companies or funds mentioned. If you want support before making any investment decisions, consider seeking financial advice from a licensed provider. We’ve done our best to ensure all information is current when we pushed ‘publish’ on this article. And of course, with investing, your money isn’t guaranteed to grow and there’s always a risk you might lose money.

Join the Kiwis who are hatching their tomorrow and have invested more than $1 billion with Hatch.

Explore another series
Tax
Money
Economy
Investing

More recent news articles

Recent learn articles

4 min read
May 29, 2025

Gen Z gains spending power - who gets their dollar?

What’s your investment timeline? If you’re planning on investing through the next five years, you might consider factoring in how the population will change in that time. Gen Z's impending economic dominance, values, and the unique challenges they face could have a transformative impact on markets and consumer behavior.
Read more
7 min read
May 6, 2025

Trump approval ratings and comfort eating stocks slump

Some Americans may have lost faith in Trump’s handling of the economy, and low and middle income earners have pushed pause on dining out, with iconic fast dining chains taking the hit. So which sector has risen in the wake?
Read more
7 min read
Apr 15, 2025

EV market rising but Tesla sales decline

Predicted by some to become a US $1.58 trillion dollar market globally, in the US alone EV sales are up 11.4% year-over-year. Which countries are leading the fast-charge? And how could trade tariffs impact sales as we accelerate into the second quarter?
Read more

Related news articles

More recent learn articles

No items found.

Recent news articles

More recent learn articles

4 min read
May 29, 2025

Gen Z gains spending power - who gets their dollar?

What’s your investment timeline? If you’re planning on investing through the next five years, you might consider factoring in how the population will change in that time. Gen Z's impending economic dominance, values, and the unique challenges they face could have a transformative impact on markets and consumer behavior.
Read more
7 min read
May 6, 2025

Trump approval ratings and comfort eating stocks slump

Some Americans may have lost faith in Trump’s handling of the economy, and low and middle income earners have pushed pause on dining out, with iconic fast dining chains taking the hit. So which sector has risen in the wake?
Read more
7 min read
Apr 15, 2025

EV market rising but Tesla sales decline

Predicted by some to become a US $1.58 trillion dollar market globally, in the US alone EV sales are up 11.4% year-over-year. Which countries are leading the fast-charge? And how could trade tariffs impact sales as we accelerate into the second quarter?
Read more